CCM
ALNY icon

Coldstream Capital Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Coldstream Capital Management’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$414K Buy
1,375
+24
+2% +$7.24K 0.01% 828
2026
Q1 		$447K Sell
1,351
-223
-14% -$75.9K 0.01% 774
2025
Q4 		$626K Sell
1,574
-66
-4% -$29.2K 0.01% 619
2025
Q3 		$748K Buy
1,640
+38
+2% +$15.5K 0.01% 560
2025
Q2 		$522K Buy
1,602
+523
+48% +$145K 0.01% 636
2025
Q1 		$291K Sell
1,079
-34
-3% -$8.74K 0.01% 826
2024
Q4 		$262K Sell
1,113
-98
-8% -$25.8K 0.01% 892
2024
Q3 		$329K Buy
1,211
+368
+44% +$95.8K 0.01% 791
2024
Q2 		$205K Buy
+843
New +$133K 0.01% 936

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Coldstream Capital Management's ALNY Position: Q2 2026 in Review

Coldstream Capital Management increased its Alnylam Pharmaceuticals (ALNY) stake by 1.8% in Q2 2026, buying an estimated $7.24K and bringing the position to 1,375 shares worth $414K. The position accounts for 0.01% of the portfolio, ranked #828.

Coldstream Capital Management first reported a position in ALNY in Q2 2024 and has held it in 9 quarters since. The position peaked at $748K in Q3 2025. 793 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Coldstream Capital Management held 1,375 shares of Alnylam Pharmaceuticals worth $414K as of Q2 2026.
  • Coldstream Capital Management bought 24 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $7.24K.
  • Alnylam Pharmaceuticals made up 0.01% of Coldstream Capital Management's portfolio in Q2 2026, its #828 holding.
  • Coldstream Capital Management first reported a position in Alnylam Pharmaceuticals in Q2 2024 and has held it in 9 quarters since.
  • Coldstream Capital Management's Alnylam Pharmaceuticals position peaked at $748K in Q3 2025.
  • 793 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Coldstream Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.